Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma. The participant was treated with both DV-10 and ide-cel… Read More
Biotech companies Dispatch Bio and CARsgen Therapeutics have announced a clinical collaboration to develop innovative CAR-T cell therapies. The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s Flare platform. This includes DV-10, the company’s novel tumour-specific virus, and CARsgen’s zevorcabtagene autoleucel (zevor-cel), an autologous B-cell maturation… Read More
Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours. Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment. Dispatch’s Flare platform has… Read More
